Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland Abstract #2746

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Aim(s): We aim to define new immunohistochemical markers expressed by specific GEP-NET subgroups with prognostic or predictive value and potential new therapy targets.
Materials and methods: At the ENETS CoE Zurich tissue microarray (TMA) blocks were constructed with 147 tissue samples of tumors diagnosed from 2000 to 2017, including primary tumors and metastasis. Tissue microarray sections were immunostained for SOX-9, SOX-10, SSTR-2 +, PDL-1, thyroid transcription factor 1 (TTF1), estrogen receptor-α (ER-α) and -β (ER-β), progesterone receptor (PR), androgen receptor (AR), BRAF and HER2.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr.med. Alexander Siebenhüner

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy
Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Yong-Il Kim
#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes
Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
Authors: Kong G, Callahan J, Prall O, Michael M, ...
#2844 Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis
Introduction: Although rectal neuroendocrine tumors (NETs) with L-cell phenotype and small tumor size generally had better clinical behavior, the new 2019 WHO classification classified all rectal NETs are malignant without considering L-cell phenotype and small tumor size. Therefore, identifying biomarkers of rectal NETs is important to stratify the clinical behavior of rectal NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: M.D. Jisup Kim
Authors: Kim J, Kim J Y, Oh E H, Yang D H, ...
#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Tao Cui
Authors: Cui T, Ryberg U, Li S C, Cunningham J, ...
#1483 Biomarker and Target Identification in GEP-NET: From in Silico Prediction to Validation on Patient Tissues
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors. Somatostatin agonist treatment has a key role in the management of GEP-NET. However, the prognosis of these tumors varies between individuals. There is, therefore, a need to identify novel prognostic and predictive biomarkers of therapeutic efficacy, as well as to propose novel therapeutic strategies.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Pascale Plas
Keywords: GPCR, miR